Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Program: Scientific Session
General Topic: Clinical

GLP1 Agonists in Rheumatic Disease and Osteoarthritis: Should We Give Them to Everyone?

Monday, October 27, 2025
10:00 AM – 11:30 AM Central Time

    Moderator(s)

  • MJ

    Matlock Jeffries, MD, FACP, FACR

    Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma, United States

    Disclosure information not submitted.

  • Nancy Lane, MD, BA

    University of California at Davis, School of Medicine
    Hillsborough, California, United States

    Disclosure(s): Merck: Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Novo Nordisk: Consultant (Ongoing)

    • Session Coordinator(s)

  • MJ

    Matlock Jeffries, MD, FACP, FACR

    Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma, United States

    Disclosure information not submitted.

  • Nancy Lane, MD, BA

    University of California at Davis, School of Medicine
    Hillsborough, California, United States

    Disclosure(s): Merck: Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Novo Nordisk: Consultant (Ongoing)

TBD

Learning Objectives:

  • Discuss the pharmacosurveillance evidence for GLP1 agonist effects and risks
  • Differentiate anti-obesity and anti-inflammatory effects of GLP1 drugs
  • Appraise the evidence for and against GLP1 drugs in clinical knee OA

Presentations:

  • 10:00 AM – 10:30 AM Central Time
    The Effectiveness of GLP-1 Agonists in Rheumatic Diseases
  • 10:30 AM – 11:00 AM Central Time
    GLP1 Agonists in Knee Osteoarthritis: A Clinical Revolution?

    Speaker: C. Thomas Appleton, MD, PhD, FRCPC – The University of Western Ontario

  • 11:00 AM – 11:30 AM Central Time
    GLP1 Agonists in Osteoarthritis: Preclinical Studies

    Speaker: Francis Berenbaum, MD, PhD – Sorbonne University - Saint-Antoine hospital